Literature Title | First Author | Type | Publication Year | Publication Journal | Brief Summary | Clinical Practice Pearl | Reference # |
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension | Wilding | Original Research | 2022 | Diabetes, Obesity, and Metabolism Journal of Pharmacology and Therapeutics | Cessation of semaglutide as a therapeutic intervention resulted in a return to baseline weight comparable to the weight before starting on semaglutide | Overweight and obesity appear to be a chronic disease that may require ongoing pharmacological intervention to halt its progression and abate its related comorbidities. | 18 |
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide | Sherwin | Observational Prospective Study || Original Research | 2023 | NIH PMC Pub Med Central | Use of gastric ultrasound to assess fat content in gastric tissue after eight hours since semaglutide dose; there was slowing of gastric emptying in the semaglutide group and higher risk for aspiration if under general anesthesia. | Semaglutid prolongs satiety in patients by slowing gastric emptying; treatment withdrawal may be beneficial prior to undergoing surgery with general anesthesia. | 19 |